Faculty

Institution

Unit

Venue

Devaki Shilpa Surasi

The University of Texas MD Anderson Cancer Center

Affiliations

Center For Nuclear Receptors And Cell Signaling

NoneDevaki Shilpa Surasi is currently serving as a Center For Nuclear Receptors And Cell Signaling faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Devaki Shilpa Surasi

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology pharmacology urology radiation oncology genitourinary cancers cancer treatment kidney cancer cancer immunotherapy pharmacotherapy medicinal research renal medullary carcinoma immunology nephrology cancer research immunotherapy cancer care tumor biology surgical oncology cancer discovery cancer cells gastrointestinal oncology positron emission tomography tumor targeting immune checkpoint inhibitors 18f-fluciclovine pet/ct metastasis oncogenes thoracic oncology virus eradication medical virology jama oncology cancer imaging histopathology nuclear medicine clinical microbiology digestive diseases treatment and prevention anti-cancer agents malignant disease clinical immunology breast oncology lymphatic disease vaccine safety covid-19 pandemic oncologic imaging abdominal imaging liver cancer hepatocellular carcinoma radiation therapy hepatobiliary tumors pet-mri diagnostic neuroradiology randomized controlled trials experimental therapeutics therapeutic efficacy novel therapies immunoediting cancer immunosurveillance bevacizumab plus erlotinib durable responses 68ga-dotatate uptake covid-19 vaccination axillary lymphadenopathy induced transarterial radioembolization failure patterns unresectable hepatocellular carcinoma treatment-naïve patients phase 1b/2 radium-223 immunomodulates bone-tumor microenvironment spatial immune profiling

Notable Scholarly Works

Notable Federal Grants

Collaborators

[18F]Dasa-23 Pet/Mri Evaluation in Newly-Diagnosed and Recurrent High-Grade Glioma. Neuroradiology (2026)

neuroradiologyneuro-oncologymedical imagingbrain tumor researchpet-mrigliomasradiologyneurologypositron emission tomographydiagnostic neuroradiologyneuroimaging

Phase 1B/2 Study of Combination 177 Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment-NaïVe Patients With Advanced Clear Cell Rcc.. Journal of Clinical Oncology (2026)

hematologycancer immunotherapycellular therapymedicinetherapeutic efficacyoncologynovel therapiestreatment-naïve patientsimmune checkpoint inhibitorsimmunotherapyphase 1b/2pharmacologycancer treatmentexperimental medicinepharmacotherapymedicinal researchclinical trials

Spatial Immune Profiling of Bone-Metastatic Castration-Resistant Prostate Cancer Reveals Radium-223 Immunomodulates the Bone-Tumor Microenvironment. Prostate Cancer and Prostatic Diseases (2025)

cancer immunotherapycellular therapyradiation oncologycancer cellsimmunotherapycancer immunosurveillanceimmunologyimmunoeditingcancer discoveryprostate cancertumor targetingbone-tumor microenvironmenttumor microenvironmentradium-223 immunomodulatesspatial immune profiling

Detection of Adenocarcinoma of the Colon on 18F-Fluciclovine Pet/Ct. Clinical Nuclear Medicine (2024)

gastroenterologycancer imagingoncologyhistopathologynuclear medicine18f-fluciclovine pet/ctoncologic imagingpositron emission tomographyradiologymedical imagingpathologyabdominal imaging

523 Nivolumab and Ipilimumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma at MD Anderson Cancer Center. Regular and Young Investigator Award Abstracts (2023)

Jaanki KhandelwalDevaki S SurasiSergio P KlimkowskyNathaniel WilsonMohammad J MoussaMatthew CampbellAmishi ShahEric JonaschAndrew HahnElshad HasanovJianjun GaoSangeeta GoswamiPavlos MsaouelPriya RaoKanishka SircarNizar TannirOmar Alhalabi

urologycancer immunotherapytranslational medicineclinical investigationcellular therapyclinical transplantationoncologyradiation oncologyrandomized controlled trialsgenitourinary cancersimmune checkpoint inhibitorsexperimental therapeuticspharmacologytherapeutic targetstumor targetingexperimental medicinemedicinal researchclinical trials

Adiposity and Response to Androgen Signaling Inhibition (Asi) in Men With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).. Journal of Clinical Oncology (2021)

Andrew Warren HahnRebecca TidwellDevaki Shilpa SurasiPatrick Glen PilieDaniel FrigoSumit Kumar SubudhiEleni EfstathiouAmado J. ZuritaShi-Ming TuBrian Francis ChapinDavid R. FogelmanMichael W StarbuckPaul G. CornAna AparicioJennifer Leigh McQuadeChristopher Logothetis

urologyoncologycancer researchcancer carepharmacologyprostate cancerneurologyclinical research

Disease Control and Failure Patterns of Unresectable Hepatocellular Carcinoma Following Transarterial Radioembolization With Yttrium-90 Microspheres and With/Without Sorafenib. World Journal of Gastroenterology (2021)

Ajalaya TeyateetiArmeen MahvashJames LongMohamed AbdelsalamRony AvritscherAhmed KasebBruno OdisioGregory RavizziniDevaki SurasiAchiraya TeyateetiHomer MacapinlacSrinivas Cheenu Kappadath

unresectable hepatocellular carcinomaradiation therapysurgical pathologyhepatocellular carcinomacarcinogenesistumor biologygastroenterologyoncologyliver cancerclinical microbiologyhepatobiliary tumorsdigestive diseasesradiation oncologygastrointestinal oncologyvascular biologyradiologyfailure patternssurgical oncologypathogenesistransarterial radioembolizationpathology

Durable Responses in Patients With Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge After Moderate-To-Severe Immune-Related Adverse Events. Journal for ImmunoTherapy of Cancer (2021)

Bilal A SiddiquiJinesh S GheeyaRohit GoswamyTharakeswara K BathalaDevaki Shilpa SurasiJianjun GaoAmishi ShahMatthew T CampbellPavlos MsaouelSangeeta GoswamiJennifer WangAmado J ZuritaEric JonaschPaul G CornAna M AparicioArlene O Siefker-RadtkePadmanee SharmaSumit K SubudhiNizar Tannir

cancer immunotherapyimmune responsesimmunotherapyclinical immunologyimmunologydurable responses

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients With Renal Medullary Carcinoma. Cancers (2021)

metastasisurologyoncologygenitourinary cancersrenal medullary carcinomacancer carepharmacologycancer treatmentnephrologykidney cancerpharmacotherapybevacizumab plus erlotinib

Efficacy and Safety of Gemcitabine Plus Doxorubicin in Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer (2021)

Nathaniel R. WilsonAndrew J. WieleDevaki Shilpa SurasiPriya RaoKanishka SircarPheroze TamboliAmishi Y. ShahGiannicola GenoveseJose A. KaramChristopher G. WoodNizar M. TannirPavlos Msaouel

pharmacologyurologytumor biologyoncologycancer researchrenal medullary carcinomatreatment and preventionmalignant diseasecancer discoveryanti-cancer agentsradiation oncologygastrointestinal oncologygenitourinary cancersnephrologymedicinal researchsurgical oncologyoncogenesthoracic oncologykidney cancer

1
2
10 / page

Devaki Shilpa Surasi

The University of Texas MD Anderson Cancer Center

Affiliations

Center For Nuclear Receptors And Cell Signaling

NoneDevaki Shilpa Surasi is currently serving as a Center For Nuclear Receptors And Cell Signaling faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Devaki Shilpa Surasi

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

[18F]Dasa-23 Pet/Mri Evaluation in Newly-Diagnosed and Recurrent High-Grade Glioma. Neuroradiology (2026)

neuroradiologyneuro-oncologymedical imagingbrain tumor researchpet-mrigliomasradiologyneurologypositron emission tomographydiagnostic neuroradiologyneuroimaging

Phase 1B/2 Study of Combination 177 Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment-NaïVe Patients With Advanced Clear Cell Rcc.. Journal of Clinical Oncology (2026)

Spatial Immune Profiling of Bone-Metastatic Castration-Resistant Prostate Cancer Reveals Radium-223 Immunomodulates the Bone-Tumor Microenvironment. Prostate Cancer and Prostatic Diseases (2025)

Detection of Adenocarcinoma of the Colon on 18F-Fluciclovine Pet/Ct. Clinical Nuclear Medicine (2024)

gastroenterologycancer imagingoncologyhistopathologynuclear medicine18f-fluciclovine pet/ctoncologic imagingpositron emission tomographyradiologymedical imagingpathologyabdominal imaging

523 Nivolumab and Ipilimumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma at MD Anderson Cancer Center. Regular and Young Investigator Award Abstracts (2023)

Adiposity and Response to Androgen Signaling Inhibition (Asi) in Men With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).. Journal of Clinical Oncology (2021)

urologyoncologycancer researchcancer carepharmacologyprostate cancerneurologyclinical research

Ajalaya TeyateetiArmeen MahvashJames LongMohamed AbdelsalamRony AvritscherAhmed KasebBruno OdisioGregory RavizziniDevaki SurasiAchiraya TeyateetiHomer MacapinlacSrinivas Cheenu Kappadath

cancer immunotherapyimmune responsesimmunotherapyclinical immunologyimmunologydurable responses

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients With Renal Medullary Carcinoma. Cancers (2021)

metastasisurologyoncologygenitourinary cancersrenal medullary carcinomacancer carepharmacologycancer treatmentnephrologykidney cancerpharmacotherapybevacizumab plus erlotinib

Efficacy and Safety of Gemcitabine Plus Doxorubicin in Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer (2021)

Nathaniel R. WilsonAndrew J. WieleDevaki Shilpa SurasiPriya RaoKanishka SircarPheroze TamboliAmishi Y. ShahGiannicola GenoveseJose A. KaramChristopher G. WoodNizar M. TannirPavlos Msaouel

1
2
10 / page